Evidence map›Paper›PMID 32641738›Full record

ArticleProstate cancer and prostatic diseases2020

The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.

Hanan Goldberg, Faizan K Mohsin, Refik Saskin, Girish S Kulkarni, Alejandro Berlin, Miran Kenk, Christopher J D Wallis, Thenappan Chandrasekar, Zachary Klaassen, Olli Saarela and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Hanan GoldbergDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada. gohanan@gmail.com.ORCID http://orcid.org/0000-0002-5777-2138
Faizan K MohsinDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Refik SaskinInstitute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Girish S KulkarniDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Alejandro BerlinDepartment of Radiation Oncology, University of Toronto; and Techna Institute, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1880-6905
Miran KenkDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Christopher J D WallisDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5990-4026
Thenappan ChandrasekarDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2173-5028
Zachary KlaassenDivision of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Olli SaarelaDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Linda PennDepartment of Medical Biophysics, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Shabbir M H AlibhaiInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.
Neil FleshnerDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
University Health Network · CAUniversity of Toronto · CAAugusta University · USInstitute for Clinical Evaluative Sciences · CAThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton pump inhibitors (PPIs) are commonly prescribed medications that have been shown to have contradicting effects on cancer. We aimed to investigate the effect of pantoprazole and other PPIs on prostate cancer (PCa) specific mortality (PCSM), use of androgen deprivation therapy (ADT), and PCa diagnosis using a large Canadian population-based cohort.

methodsWe identified 21,512 men aged ≥ 66, with a history of a single negative prostate biopsy and no previous use of any of the analyzed medications between 1994 and 2016. Multivariable Cox regression models with time-dependent covariates were used to assess the associations of PPIs with PCa outcomes. All models included other medications with a putative chemopreventative effect on PCa-outcomes, and were adjusted for age, rurality, comorbidity, and study inclusion year.

resultsOver a mean follow-up of 8.06 years (SD 5.44 years), 10,999 patients (51.1%) used a PPI, 5187 patients (24.1%) had PCa, 2043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. For every 6 months of cumulative use, pantoprazole was associated with a 3.0% (95% CI 0.3-6.0%) increased rate of ADT use, while any use of other PPIs was associated with a 39.0% (95% CI 18.0-64.0%) increased risk of PCSM. No association was found with PCa diagnosis.

conclusionsUpon validation of the potentially negative association of PPIs with PCa, PPI use may need to be reassessed in PCa patients.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsCanadaCohort StudiesComorbidityHumansMaleProstatic NeoplasmsProton Pump InhibitorsRetrospective StudiesRisk FactorsSurvival RateAndrogen AntagonistsProton Pump Inhibitors

Identifiers

PMID32641738
OpenAlexW3040939293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.